Related Experiment Video
Updated: Jan 3, 2026
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
Published on: May 2, 2025
Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors
Miriam Bornhorst1,2,3, Eugene I Hwang4,5
1Department of Pediatric Hematology-Oncology, Center for Cancer and Immunology Research and Neuroscience Research, Children's National Medical Center, 111 Michigan Ave, NW, Washington, DC, 20010, USA.
Abstract:
Pediatric brain tumors are the leading cause of cancer-related death in children. Recent advances in sequencing techniques, and collaborative efforts to encode the mutational landscape of various tumor subtypes, have resulted in the identification of recurrent mutations that may present as actionable targets in these tumors. A number of molecularly targeted agents are approved or in development for the treatment of various tumor types in adult patients. Similarly, these agents are increasingly being incorporated into pediatric clinical trials, allowing for a targeted approach to treatment. However, due to the genetic heterogeneity of these tumors, focused clinical trials in pediatric patients are challenging and regulatory hurdles may delay access to therapeutic compounds that are in regular use in adult patients. The tumor site-agnostic clinical development of TRK inhibitors for pediatric solid tumors is a current example of how the combination of genetic testing and innovative clinical trial design can accelerate the clinical development of targeted agents for pediatric patients.
Insights
Pediatric brain tumors are a leading cause of childhood cancer death. Advances in genetic testing and targeted therapies, like TRK inhibitors, offer new treatment avenues for children with these challenging tumors.
Area of Science:
- Oncology
- Pediatric Oncology
- Molecular Biology
Background:
- Pediatric brain tumors represent the primary cause of cancer-related mortality in children.
- Advances in genomic sequencing have identified actionable mutations in various pediatric tumor subtypes.
- Targeted therapies, initially developed for adult cancers, are increasingly being investigated for pediatric applications.
Purpose of the Study:
- To explore the potential of molecularly targeted agents in treating pediatric brain tumors.
- To highlight the challenges and opportunities in developing targeted therapies for pediatric oncology.
- To showcase innovative clinical trial designs for pediatric cancer treatment.
Main Methods:
- Review of recent advances in sequencing techniques and collaborative efforts in tumor mutational landscape encoding.
- Analysis of the incorporation of molecularly targeted agents into pediatric clinical trials.
- Examination of the tumor site-agnostic development of TRK inhibitors in pediatric solid tumors.
Main Results:
- Recurrent mutations in pediatric tumors are being identified as potential therapeutic targets.
- Targeted agents are being integrated into pediatric clinical trials, enabling personalized treatment approaches.
- The development of TRK inhibitors demonstrates the success of combining genetic testing with novel clinical trial designs.
Conclusions:
- Genetic testing and innovative clinical trial designs can accelerate the development of targeted therapies for pediatric patients.
- Overcoming challenges like genetic heterogeneity and regulatory hurdles is crucial for advancing pediatric cancer treatment.
- The successful development of TRK inhibitors offers a model for future targeted therapy advancements in pediatric oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...